An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines

[1]  J. Kanis,et al.  FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan , 2021, Archives of Osteoporosis.

[2]  J. Kanis,et al.  Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden , 2021, Osteoporosis International.

[3]  J. Kanis,et al.  The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture , 2020, Osteoporosis International.

[4]  J. Kanis,et al.  Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures , 2020, Osteoporosis International.

[5]  P. Geusens,et al.  Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial , 2020, Osteoporosis International.

[6]  C. Cooper,et al.  Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.

[7]  J. Kanis,et al.  Characteristics of recurrent fractures , 2018, Osteoporosis International.

[8]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[9]  J. Kanis,et al.  FRAX-based intervention and assessment thresholds in seven Latin American countries , 2018, Osteoporosis International.

[10]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[11]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[12]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[13]  C. Cooper,et al.  A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.

[14]  J. Kanis,et al.  FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.

[15]  J. Kanis,et al.  Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.

[16]  C. Cooper,et al.  FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.

[17]  M. Cowie National Institute for Health and Care Excellence. , 2015, European heart journal.

[18]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[19]  Naoto Endo,et al.  Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.

[20]  T. Sone,et al.  Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  C. Cooper,et al.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.

[22]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[23]  J. Kanis,et al.  Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.

[24]  C. Cooper,et al.  The cost-effectiveness of alendronate in the management of osteoporosis. , 2008, Bone.

[25]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.